Current Events

Hyundai is recalling 5,200 model-year 2012-13 Azera sedans due to a problem with the airbag system that could prevent it from recognizing whether a passenger is an adult or a child, according to the National Highway Traffic Safety Administration.

Affected vehicles were manufactured between May 22 and Nov. 23, 2012. The occupant detection system may fail to properly differentiate whether the front passenger-seat occupant is an adult, a child or a child-safety seat; if this happens during a crash in which airbags deploy, the affected airbag may respond with greater or lesser force than appropriate, increasing the risk of an injury. Jim Trainor, Hyundai spokesman, said the automaker believes the actual number of vehicles with the problem will be "less than 1 percent" of the 5,200 included in the recall.

Click here to read more.

The National Highway Traffic Safety Administration is investigating owner complaints of unexpected braking and whether there should be a recall of almost 344,000 Honda Odyssey minivans from the 2007-8 model years. The complaints are similar to those that resulted in the recall of about 183,000 different Honda and Acura models in March.

The safety agency says it decided to investigate after receiving 22 complaints from Odyssey owners saying “that the vehicle suddenly applies the brakes by itself,” according to a report posted Saturday on the N.H.T.S.A. Web site.

Click here to read more.

The Food and Drug Administration said on Friday that it had identified another product contaminated with Hepatitis A, which was the cause of a recall of frozen organic berries earlier this month.

As a result, the Scenic Fruit Company of Gresham, Ore., has recalled three different lots of its Woodstock Frozen Organic Pomegranate Kernels, which were shipped from February through May to United Natural Foods Inc. distribution centers in 12 states – California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa, New Hampshire, Pennsylvania, Rhode Island, Texas and Washington.

Click here to read more.

PETER DOSHI walked across the campus of Johns Hopkins University in a rumpled polo shirt and stonewashed jeans, a backpack slung over one shoulder. An unremarkable presence on a campus filled with backpack-toters, he is 32, and not sure where he’ll be working come August, when his postdoctoral fellowship ends. And yet, even without a medical degree, he is one of the most influential voices in medical research today.

Dr. Doshi’s renown comes not from solving the puzzles of cancer or discovering the next blockbuster drug, but from pushing the world’s biggest pharmaceutical companies to open their records to outsiders in an effort to better understand the benefits and potential harms of the drugs that billions of people take every day. Together with a band of far-flung researchers and activists, he is trying to unearth data from clinical trials — complex studies that last for years and often involve thousands of patients across many countries — and make it public. 

Click here to read more.

The Ford Motor Co. said Thursday it will recall about 13,100 vehicles for door latches that may fail and cause child safety locks to deactivate.

The Dearborn automaker will recall three 2013 model-year vehicles — the Explorer SUV, Taurus sedan and Lincoln MKS sedan — built at Ford’s Chicago Assembly Plant.

Upon opening or closing a door, the child safety lock may change from “activated” to “deactivated.”

Ford said that no accidents or injuries have been reported.

Click here to read more.

Medtronic Inc. (MDT)’s SynchroMed infusion pumps were found to have four flaws that have led to 14 patient deaths, spurring U.S. regulators to issue their most serious recall on the implantable device used to deliver pain and other medications.

Medtronic, the world’s largest heart device maker, notified customers in early June about the flaws that may interfere with the safe and reliable delivery of medications using the SynchroMed Implantable Infusion System, the Minneapolis-based company said in a statement. Each flaw specified in the notifications was deemed a Class 1 recall by the U.S. Food and Drug Administration, denoting potential life-threatening issues.

Click here to read more.

In the wake of Monday's Supreme Court decision that blocked the ability of patients to sue generic drugmakers for design flaws in their medicine because it would conflict with Food and Drug Administration rules, members of Congress and consumer groups renewed their plea to the FDA to change those rules. A link to Tuesday's Inquirer story is here.

Three senators and four representatives - all Democrats - sent a letter to FDA Commissioner Margaret Hamburg, urging her to make the changes happen so that patients who think they are harmed can seek redress in state courts.

Karen Bartlett was the plaintiff in the case that was decided Monday. The New Hampshire woman took a generic painkiller made by Philadelphia's Mutual Pharmaceutical Co., which is now part of Sun Pharmaceutical Industries, Ltd. Her adverse reaction included terrible skin reactions, near blindness, 12 operations and the need for a medically-induced coma.

Click here to read more.

WASHINGTON - First Karen Bartlett lost more than 60% of her skin, suffered lung and esophageal damage and became legally blind after taking a generic painkiller. Now the Supreme Court has stripped her of a $21 million state court award.

In another example of its well-documented pro-business tilt, the high court ruled Monday that the generic drug maker wasn't liable for the painkiller's content or warning label because it must mimic the brand-name drug in both instances.

Not that the justices didn't sympathize with Bartlett's plight. The 5-4 decision, written by Justice Samuel Alito, said the case "arises out of tragic circumstances" and spread blame at the feet of doctors, Congress and the Food and Drug Administration.

Click here to read more.

The Food and Drug Administration is charged with protecting the public health, but some of its recent actions raise serious questions about drug safety.

One puzzle is its shifting stance on the diabetes drug rosiglitazone (Avandia). Several years ago, Avandia was marketed aggressively and widely prescribed. In its heyday, it earned more than $3 billion a year, making it the most successful diabetes drug of all time. Then cardiologist Steve Nissen, M.D., published an article in the New England Journal of Medicine (June 14, 2007) revealing a 43 percent increased risk of heart attack among patients taking Avandia.

Click here to read more.

WASHINGTON - The Food and Drug Administration is tightening standards for a wide range of medical devices – from fetal monitors used in hospitals to pacemakers implanted in people – because of escalating concerns that the gadgets are vulnerable to cybersecurity breaches that could harm patients.

Increasingly, officials said, computer viruses and other malware are infecting equipment such as hospital computers used to view X-rays and CT scans as well as devices in cardiac catheterization labs. The security breaches cause the equipment to slow down or shut off entirely, complicating patient care. As more devices operate on computer systems that are connected to each other, the hospital network and the Internet, the potential for problems rises dramatically, they said.

Click here to read more.

The ongoing outbreak of hepatitis A linked to a frozen berry mix sold at Costco is now known to have sickened 119 people in the western United States, according to an update from the Centers for Disease Control and Prevention.

Of these victims, 53 have been hospitalized as a result of their infections. CDC last reported 50 hospitalizations and 113 cases, meaning that 3 of the 6 newly reported cases were hospitalizations.

Click here to read more.